HiSeq Sales Boost Illumina's Q3 Revenues, but Order Backlog Will Take Several Quarters to Fill

Nov 02, 2010

Premium

This article was originally published Oct. 27.

By Julia Karow

Illumina said last week that demand for the HiSeq 2000 continued to exceed its expectations during the third quarter, prompting it to further increase production of the instrument.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

DNA Tests Considered to Verify Relatedness at Border

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

First of 'Right to Try'

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.